Pioneering T-cell Immunotherapy for Liver Cancer

Lion TCR’s Breakthrough in Hepatitis B-related Cancer Treatment

In collaboration with A*STAR, Lion TCR is advancing treatment for Hepatitis B-related liver cancer through its innovative T-cell immunotherapy. As the first in the world to develop HBV-specific TCR-T cell therapy, Lion TCR addresses a critical unmet medical need in cancer care. With FDA Fast Track Designation and clinical trials underway, Lion TCR is bringing hope to patients with limited treatment options. Their proprietary therapy, developed in partnership with leading institutions, aims to improve outcomes for patients with chronic Hepatitis B and liver cancer globally.

The objectives

Developing Innovative T-cell Immunotherapy

Lion TCR aims to address the significant unmet need for effective treatment options for Hepatitis B-related liver cancer by pioneering T-cell immunotherapy. With this technology, the company seeks to provide patients with an alternative to conventional treatments, particularly for those with limited options, by harnessing the body’s immune response to target liver cancer.

Fast-Tracking Clinical Development

Securing FDA Fast Track Designation for their lead product, LioCyx-M004, Lion TCR is focused on accelerating the approval process for its therapy. This designation underscores the potential of Lion TCR’s immunotherapy to meet urgent medical needs and enables the company to bring its life-changing treatment to patients more swiftly.

Expanding Intellectual Property and R&D Capabilities

To maintain a competitive advantage, Lion TCR is building its intellectual property portfolio and strengthening its in-house research capabilities. By leveraging A*STAR’s T-Up programme, the company has seconded scientists to optimise product development and scale production. This effort is part of a broader strategy to establish a sustainable innovation pipeline and bring new therapies to clinical trials.

Access scientific expertise with A*STAR’s T-Up programme.

Find Out More

The impact

Lion TCR’s innovative approach to liver cancer treatment has had a profound impact on the field of immunotherapy, particularly for patients with Hepatitis B-related liver cancer. By developing the world’s first HBV-specific TCR-T cell therapy, Lion TCR is paving the way for new treatment modalities that go beyond traditional options like surgery and liver transplantation. This breakthrough offers hope to patients with few alternatives, especially those with recurrent or late-stage disease.

Through the partnership with A*STAR and the T-Up programme, Lion TCR has accelerated its research and development efforts, bringing therapies from lab-scale research to clinical trial-ready products. The FDA Fast Track Designation for their lead therapy, LioCyx-M004, underscores the significance of their work and highlights the potential to meet urgent medical needs. This designation not only expedites the approval process but also supports Lion TCR’s mission to provide effective cancer treatments in a timely manner.

Moreover, the expertise gained from A*STAR has enabled Lion TCR to build the largest patented HBV-specific TCR library, covering approximately 80 percent of the global population. This advancement positions Lion TCR as a global leader in liver cancer immunotherapy, capable of addressing the needs of a wide patient base. By leveraging technology licensing and strategic partnerships, Lion TCR has created a robust platform for further innovation and expansion.

Lion TCR’s work represents a vital step forward in cancer treatment and serves as a model for how collaboration and cutting-edge research can lead to life-changing therapies. As they continue to grow, Lion TCR remains committed to pushing the boundaries of what is possible in immunotherapy, offering new hope for patients around the world.